HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.
about
Genetic testing for prevention of severe drug-induced skin rashPathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and backEvolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity.HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis.Genotyping for severe drug hypersensitivity.The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective reviewRecommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.T cell-mediated hypersensitivity reactions to drugsPharmGKB summary: very important pharmacogene information for human leukocyte antigen B.Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 - 2015Antecedent Drug Exposure Aetiology and Management Protocols in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis, A Hospital Based Prospective StudyThe HLA-A*31:01 allele: influence on carbamazepine treatmentThe emerging era of pharmacogenomics: current successes, future potential, and challenges.Pharmacogenetics of antiepileptic drug-induced hypersensitivity.Recent advances in the understanding of severe cutaneous adverse reactions.Rapid detection of HLA-A*31:01 allele in DNA and blood samples using loop-mediated isothermal amplification.Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.Genetic risk factors for antiepileptic drug-induced hypersensitivity reactions in Israeli populations.A novel multiplex PCR assay for detection of both HLA-A*31:01/HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions.HLA-B*1502 in Iranian Children with Anticonvulsant Drugs-Induced Skin Reactions.HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis.Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore.Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients.PSORS1C1 Hypomethylation Is Associated with Allopurinol-Induced Severe Cutaneous Adverse Reactions during Disease Onset Period: A Multicenter Retrospective Case-Control Clinical Study in Han Chinese.SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.Antiepileptic drugs: Role in paediatric poisoning.HLA-DQA1, -DQB1, and -DRB1 Alleles Associated with Acute Tubulointerstitial Nephritis in a Chinese Population: A Single-Center Cohort Study.Mechanisms of Adverse Drug ReactionsAssociation of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population
P2860
Q24202114-540A6B86-0AF5-41AC-AE79-3B1BCFBF6951Q26784638-63EE54F3-FB93-4779-A16D-0F136F65D20DQ26800980-D142EC5B-7FDB-4160-B906-CCDDAEFA1D7BQ27692095-C2B4FC5D-FD10-4D8F-BE42-771E78012C6CQ30238992-88E18B48-53B6-40FA-8535-7F2E8195735AQ30855868-20743988-DE2A-4C0A-ABDC-34B5A9F5EB4CQ33582530-3B0A65B8-F11F-46FC-9E27-BCBE487F48FDQ34016198-EDAC5AA3-5405-4B6D-973A-314B93420D58Q34408357-FE868766-713E-439E-B35C-ACB4A2CB1FFCQ34971993-2E91B207-2B96-49D3-9993-B757FB194141Q35168561-3D0C6D18-0128-40DA-A0B3-489EE8EB016EQ36253270-57625B20-DA15-412A-ACCA-8325FE47089EQ36541832-40C0ADDF-A056-4B7F-B7F6-5B5A8F60C0A1Q37626751-F1D6E8F4-FCDB-4C2E-9542-973DA3444992Q38200683-C7F6310D-51DB-4B4E-AA93-44D42E940C1DQ38217627-39A38B58-F055-4BDF-85C7-E3B905D52C5EQ38931289-E3AF3462-3BB1-4566-95E3-2427C681D5A9Q39018771-8E3E6252-CABC-4038-9563-285CE7D948ECQ39074126-F9136B2B-13D3-4D15-B3C8-EC6DB137FE5DQ39487785-60851129-F413-4D32-81A9-46514EB67105Q40051391-AAB60AB8-B998-4243-BB9E-3F0B98019B3DQ40984481-75BACD9E-8766-4936-B34E-CAC2D46570FFQ46859144-7A8055B0-2789-4002-B69F-06565AC31912Q46910307-1EB5FEF6-AF98-4829-90C7-1205F0A3D618Q47244043-AA992586-E543-4A68-B9C4-435CE0BEB60CQ49247755-4333D33C-7B49-4F1B-BBB2-86ABAEE1809EQ50115047-8C51136A-8A17-452B-BD26-88CB7B90578EQ50424163-9C60012F-3FA3-4CCA-B8A0-8E3261B47D7FQ55488653-E478EED9-A143-4F2D-B2E7-E3D398CD8814Q57302639-0BCC4B10-A7E7-4F55-9E51-03A06A0E4016Q57557226-40A552AF-AA8A-4F8C-8110-2718C6FE39F7
P2860
HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HLA-A 31:01 and HLA-B 15:02 as ...... hypersensitivity in children.
@en
HLA-A 31:01 and HLA-B 15:02 as ...... hypersensitivity in children.
@nl
type
label
HLA-A 31:01 and HLA-B 15:02 as ...... hypersensitivity in children.
@en
HLA-A 31:01 and HLA-B 15:02 as ...... hypersensitivity in children.
@nl
prefLabel
HLA-A 31:01 and HLA-B 15:02 as ...... hypersensitivity in children.
@en
HLA-A 31:01 and HLA-B 15:02 as ...... hypersensitivity in children.
@nl
P2093
P2860
P356
P1476
HLA-A 31:01 and HLA-B 15:02 as ...... e hypersensitivity in children
@en
P2093
C J D Ross
CPNDS Consortium
L I Castro-Pastrana
M J Rieder
M R Hayden
P2860
P304
P356
10.1038/CLPT.2013.55
P407
P577
2013-03-18T00:00:00Z